Atyr Pharma Stock Market Value
| ATYR Stock | 0.89 0.04 4.30% |
| Symbol | ATyr |
Can Biotechnology industry sustain growth momentum? Does ATyr have expansion opportunities? Factors like these will boost the valuation of ATyr Pharma. If investors know ATyr will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating ATyr Pharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of aTyr Pharma is measured differently than its book value, which is the value of ATyr that is recorded on the company's balance sheet. Investors also form their own opinion of ATyr Pharma's value that differs from its market value or its book value, called intrinsic value, which is ATyr Pharma's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because ATyr Pharma's market value can be influenced by many factors that don't directly affect ATyr Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that ATyr Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ATyr Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, ATyr Pharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
ATyr Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ATyr Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ATyr Pharma.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in ATyr Pharma on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding aTyr Pharma or generate 0.0% return on investment in ATyr Pharma over 90 days. ATyr Pharma is related to or competes with Alx Oncology, CAMP4 THERAPEUTICS, Quince Therapeutics, Metagenomi Common, Unicycive Therapeutics, Relmada Therapeutics, and Acrivon Therapeutics. ATyr Pharma is entity of United States. It is traded as Stock on NASDAQ exchange. More
ATyr Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ATyr Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess aTyr Pharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.51 | |||
| Information Ratio | 0.046 | |||
| Maximum Drawdown | 35.2 | |||
| Value At Risk | (7.95) | |||
| Potential Upside | 10.23 |
ATyr Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ATyr Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ATyr Pharma's standard deviation. In reality, there are many statistical measures that can use ATyr Pharma historical prices to predict the future ATyr Pharma's volatility.| Risk Adjusted Performance | 0.0554 | |||
| Jensen Alpha | 0.258 | |||
| Total Risk Alpha | (0.10) | |||
| Sortino Ratio | 0.0594 | |||
| Treynor Ratio | 0.2813 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ATyr Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
ATyr Pharma February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0554 | |||
| Market Risk Adjusted Performance | 0.2913 | |||
| Mean Deviation | 3.94 | |||
| Semi Deviation | 3.77 | |||
| Downside Deviation | 4.51 | |||
| Coefficient Of Variation | 1723.58 | |||
| Standard Deviation | 5.82 | |||
| Variance | 33.9 | |||
| Information Ratio | 0.046 | |||
| Jensen Alpha | 0.258 | |||
| Total Risk Alpha | (0.10) | |||
| Sortino Ratio | 0.0594 | |||
| Treynor Ratio | 0.2813 | |||
| Maximum Drawdown | 35.2 | |||
| Value At Risk | (7.95) | |||
| Potential Upside | 10.23 | |||
| Downside Variance | 20.35 | |||
| Semi Variance | 14.19 | |||
| Expected Short fall | (5.99) | |||
| Skewness | 1.8 | |||
| Kurtosis | 6.16 |
aTyr Pharma Backtested Returns
ATyr Pharma appears to be dangerous, given 3 months investment horizon. aTyr Pharma secures Sharpe Ratio (or Efficiency) of 0.1, which signifies that the company had a 0.1 % return per unit of risk over the last 3 months. By analyzing ATyr Pharma's technical indicators, you can evaluate if the expected return of 0.58% is justified by implied risk. Please makes use of ATyr Pharma's Semi Deviation of 3.77, risk adjusted performance of 0.0554, and Downside Deviation of 4.51 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, ATyr Pharma holds a performance score of 8. The firm shows a Beta (market volatility) of 1.17, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ATyr Pharma will likely underperform. Please check ATyr Pharma's sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to make a quick decision on whether ATyr Pharma's price patterns will revert.
Auto-correlation | -0.26 |
Weak reverse predictability
aTyr Pharma has weak reverse predictability. Overlapping area represents the amount of predictability between ATyr Pharma time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of aTyr Pharma price movement. The serial correlation of -0.26 indicates that nearly 26.0% of current ATyr Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.26 | |
| Spearman Rank Test | -0.23 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Pair Trading with ATyr Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ATyr Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ATyr Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against ATyr Stock
| 0.62 | RAC | Race Oncology | PairCorr |
| 0.49 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.44 | OSE | OSE Pharma SA | PairCorr |
| 0.43 | VCYT | Veracyte | PairCorr |
| 0.37 | VCEL | Vericel Corp Ord | PairCorr |
The ability to find closely correlated positions to ATyr Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ATyr Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ATyr Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling aTyr Pharma to buy it.
The correlation of ATyr Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ATyr Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if aTyr Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ATyr Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ATyr Stock Analysis
When running ATyr Pharma's price analysis, check to measure ATyr Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma is operating at the current time. Most of ATyr Pharma's value examination focuses on studying past and present price action to predict the probability of ATyr Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma's price. Additionally, you may evaluate how the addition of ATyr Pharma to your portfolios can decrease your overall portfolio volatility.